文献速递腹部MR

LI-RADS 2017版与2018版对比:钆塞酸二钠增强MRI诊断肝细胞癌

LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
PubMed 文献 · Radiology · 2019-07-16

本回顾性研究纳入387例高危患者共422个观测灶(含234个病理证实肝细胞癌),由三名放射科医师按LI-RADS 2017版与2018版分类,比较LR-5诊断肝细胞癌的敏感度与特异度。2018版整体敏感度81%高于2017版68%(P < .001);在10–19 mm小病灶中2018版敏感度76%远高于2017版11%(P < .001),特异度94% vs 99%(P = .013),仅轻度下降。

要点

  • 钆塞酸二钠增强MRI上,LI-RADS 2018版LR-5整体敏感度81%(189/234)高于2017版68%(160/234),P < .001。
  • 10–19 mm小病灶中2018版敏感度76%(34/45)远高于2017版11%(5/45),P < .001。
  • 10–19 mm病灶特异度2018版94%(121/128)低于2017版99%(127/128),P = .013,仅轻度下降。

核心结论

  • 在钆塞酸二钠增强MRI上,LI-RADS 2018版更新的LR-5标准较2017版可提高小肝细胞癌(10–19 mm)的诊断敏感度,特异度仅轻度下降。

研究设计与样本

  • 回顾性研究,纳入2013年1月至2015年10月连续的高危患者387例(男305例、女82例,平均年龄59岁±10),共422个观测灶,其中234个肝细胞癌经病理检查证实;由三名放射科医师阅片,按LI-RADS 2018版与2017版分类,采用广义估计方程模型比较LR-5的敏感度与特异度。

诊断标准与关键数值

  • 全部观测灶中LR-5诊断肝细胞癌敏感度:LI-RADS 2018版81%(189/234)vs 2017版68%(160/234),P < .001;10–19 mm观测灶中敏感度:2018版76%(34/45)vs 2017版11%(5/45),P < .001;10–19 mm观测灶中特异度:2018版94%(121/128)vs 2017版99%(127/128),P = .013。

临床应用与阅片要点

  • 作者结论认为,在钆塞酸二钠增强MRI上采用LI-RADS 2018版更新的LR-5标准,可在仅轻度损失特异度的情况下提高10–19 mm小肝细胞癌的诊断敏感度。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Few studies have reported on the diagnostic performance of Liver Imaging Reporting and Data System (LI-RADS) LR-5 or LR-5 V in the diagnosis of hepatocellular carcinoma (HCC) using MRI with gadoxetate disodium. Purpose To determine the diagnostic performance of LI-RADS version 2018 (hereafter, v2018) on gadoxetate disodium-enhanced MRI in comparison with LI-RADS version 2017 (hereafter, v2017) for the diagnosis of HCC in patients with cirrhosis or chronic hepatitis B viral infection or at high risk for HCC. Materials and Methods This retrospective study between January 2013 and October 2015 evaluated consecutive patients at high risk for HCC who had at least one observation of 10 mm or greater on gadoxetate disodium-enhanced MRI and no history of previous treatment for hepatic lesions. MRI features were reviewed by three radiologists. Observations were categorized according to LI-RADS v2018 and LI-RADS v2017. Per-observation sensitivity and specificity of LR-5 using LI-RADS v2017 and v2018 were compared using generalized estimating equation models. Results A total of 422 observations, including 234 HCCs confirmed by results of pathologic examination in 387 patients (305 men and 82 women; mean age ± standard deviation, 59 years ± 10), were included. In all observations, LI-RADS v2018 provided higher sensitivity than LI-RADS v2017 (81% [189 of 234] vs 68% [160 of 234], respectively; P < .001). In small observations (10-19 mm), LI-RADS v2018 yielded much higher sensitivity than LI-RADS v2017 (76% [34 of 45] vs 11% [five of 45], respectively; P < .001) with relatively little impairment of specificity (94% [121 of 128] vs 99% [127 of 128], respectively; P = .013). Conclusion Updated LR-5 criteria of Liver Imaging Reporting and Data System (LI-RADS) version 2018 on gadoxetate disodium-enhanced MRI can improve sensitivity in the diagnosis of small hepatocellular carcinomas (10-19 mm) with only slight impairment in specificity compared with the criteria of LI-RADS version 2017. © RSNA, 2019 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Lee SM, Lee JM, Ahn SJ, et al. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI. Radiology. 2019. PMID: 31310175. doi:10.1148/radiol.2019182867

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。